The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Patil, N. S.
Right arrow Articles by Mellins, E. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Patil, N. S.
Right arrow Articles by Mellins, E. D.
Right arrowPubmed/NCBI databases
*Substance via MeSH
The Journal of Immunology, 2001, 166: 33-41.
Copyright © 2001 by The American Association of Immunologists

Autoantigenic HCgp39 Epitopes Are Presented by the HLA-DM-Dependent Presentation Pathway in Human B Cells1

Namrata S. Patil2,*, Frances C. Hall{dagger}, Sheila Drover{ddagger}, David R. Spurrell{ddagger}, Ebo Bos§, Andrew P. Cope{dagger}, Grete Sonderstrup3,{dagger} and Elizabeth D. Mellins3,*

Departments of * Pediatric Immunology and {dagger} Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305; {ddagger} Faculty of Medicine, Memorial University of Newfoundland, St. John’s, Newfoundland, Canada; and § NV Organon, Oss, The Netherlands


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
It is hypothesized that autoimmune diseases manifest when tolerance to self-Ags fails. One possible mechanism to break tolerance is presentation of self-Ag in an altered form. Most Ags are presented by APCs via the traditional presentation pathway that includes "epitope editing" by intracellular HLA-DM, a molecule that selects for stable MHC-peptide complexes. We were interested in testing the hypothesis that autoreactive MHC-peptide complexes may reach the cell surface by an alternate pathway without being edited by HLA-DM. We selected a cartilage autoantigen human cartilage glycoprotein 39 to which T cell responses are observed in rheumatoid arthritis (RA) patients and some DR*04 healthy subjects. RA is genetically associated with certain DRB1 alleles, including DRB1*0401 but closely related allele DRB1*0402 is either neutral or mildly protective with respect to RA. We generated human B lymphoblastoid cell line cells expressing DR*0401 or DR*0402 in the presence or absence of intracellular HLA-DM and assessed their ability to present a candidate autoantigen, human cartilage glycoprotein 39. Our results show that the presence of intracellular HLA-DM is critical for presentation of this autoantigen to CD4+ T cell hybridomas generated from DR*04-transgenic mice. Presentation of an autoantigen by the traditional HLA-DM-dependent pathway has implications for Ag presentation events in RA.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Autoimmune disease represents a failure of development of tolerance to self-proteins. Studies in a variety of systems have identified several mechanisms for the generation and maintenance of self-tolerance (reviewed in Ref. 1). These mechanisms can be divided into those that operate centrally, in the thymus or bone marrow, to purge the developing repertoire of potentially self-reactive lymphocytes, and those that operate peripherally to control self-reactive responses in the periphery. Ag presentation to T cells is a key event in several of these cases. For example, in the thymus, selection on low avidity MHC ligands may allow escape of T cells with relatively high affinity for self-peptide/MHC complexes (2). Alternatively, in the periphery, self-Ags may be immunogenic if they are novel (not presented in the thymus) or presented in an altered form via a nontraditional presentation pathway (reviewed in Ref. 3). These scenarios may be particularly relevant for autoimmune diseases that are associated with MHC class II alleles (4, 5, 6).

The traditional MHC class II Ag presentation pathway selects for stable MHC/peptide complexes. Class II molecules are synthesized in the endoplasmic reticulum, assembled onto invariant chain (Ii)4 and transported to endosomes, where Ii is degraded to terminal class II-bound Ii peptides (CLIP)4 (reviewed in Refs. 7 and 8). CLIP release from class II molecules is catalyzed by HLA-DM. HLA-DM also selects for stable MHC-peptide complexes, apparently by releasing DM-unstable peptides until an optimal ligand is found (9, 10, 11).

In contrast to epitopes selected in the traditional pathway, autoantigenic peptides in several disease models bind weakly to their cognate MHC (12). For instance, encephalitogenic peptide epitopes derived from myelin basic protein, the immunizing Ag in murine autoimmune encephalitis, bind poorly to class II molecules (12, 13, 14). Low affinity epitopes have also been described for adjuvant arthritis, experimental autoimmune uveoretinitis, and experimental myasthenia gravis (12). However, some high affinity autoantigenic epitopes have also been described for autoimmune encephalitis and diabetes (15, 16, 17, 18, 19).

The low to moderate affinity of some disease-associated autoantigenic epitopes suggests that these epitopes may have been generated via an alternate pathway. Peptide epitopes of the acetylcholine receptor may also be generated via nontraditional pathways because acetylcholine receptor-reactive T cell clones obtained from healthy and diseased subjects, respond only to peptide Ag, but not to intact Ag presented by PBMC (20).

Rheumatoid arthritis (RA) is a class II-associated autoimmune disease in which certain HLA-DRB1 alleles confer both predisposition to RA and an increased risk of severity of disease (21, 22, 23). The RA-associated DRB1 alleles, including DRB1*0401 contain a short consensus sequence, called the "shared epitope" (SE) that consists of residues DRB 67, 70, 71, and 74 including positively charged residues at pocket 4 (24, 25). The SE is not present in closely related non-RA-associated alleles, such as DR*0402, implicating this region in disease pathogenesis. The crystal structure of DR*0401 with a collagen peptide shows that the SE residues contribute to peptide-binding specificity and to TCR contact (26). The SE region of RA-associated alleles may influence interaction with CLIP and/or HLA-DM. Allelic variations in interactions of MHC class II molecules with Ii and with CLIP, and their varying degrees of dependence on HLA-DM, have been described (27, 28). These allelic differences could affect the peptides bound to the class II molecules and possibly facilitate a surface display of MHC molecules bearing lower affinity autoantigenic ligands.

To assess the influence of HLA-DM on the presentation of autoantigens, we selected human cartilage glycoprotein 39 (HCgp39). HCgp39 is a major secretory product of articular chondrocytes in culture (29, 30). It is detected in inflamed synovial joints, including joints in active RA, but rarely in normal articular joints (31, 32). T cells from HLA-DR4-positive RA patients and some HLA-DR4-matched healthy individuals show a proliferative response to HCgp39 peptides (33, 34). The HCgp39 peptide epitopes used in this study have IC50 values ranging from 75 to 220 nM for soluble DR*0401 (34). These affinities are similar to the affinity of the DM-susceptible CLIP peptide for DR*0401, which has an IC50 value of 141 nM (27). In this study we assess whether, like CLIP, the HCgp39 peptides are susceptible to DM editing.

To determine whether presentation of HCgp39 autoantigenic epitopes requires the presence of intracellular HLA-DM, we used human B lymphoblastoid cells with and without intracellular HLA-DM as model APCs. These B cell lines lacked HCgp39-specific B cell receptors, hence Ag uptake is presumed to be via endocytosis. We examined responses of T cell hybridomas generated from either DR*0401- or DR*0402-transgenic mice immunized with the HCgp39 protein. We used DR*0401-restricted T cell hybridomas that respond to the same HCgp39 peptides that induce a proliferative T cell response in RA patients (34).


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Tissue culture methods

B lymphoblastoid cell lines (B-LCL) were maintained in RPMI 1640 with 15% bovine calf serum and 2 mM L-glutamine. T hybridoma cells were cultured in hypoxanthine/aminopterin/thymidine media (RPMI 1640 supplemented with 10% FCS, 2 mM L-glutamine, 10 mM HEPES, 1 mM sodium pyruvate, 50 µM 2-ME, 100 µM hypoxanthine, 0.4 µM aminopterin, and 0.016 mM thymidine). Media and supplements were purchased from Life Technologies (Gaithersburg, MD).

Generation of transfectants

The B-LCL cells used to generate HLA-DR4 transfectants were 8.1.6 and its HLA-DM-null derivative, 9.5.3. These cells are hemizygous in the DR/DQ region of the MHC and express HLA-DR3, DQ2, and DP4 (35). 9.5.3 cells do not express DMB (36). DR molecules from 9.5.3 are predominantly associated with CLIP peptides and have fewer DR3 non-CLIP-peptide complexes on the cell surface than HLA-DM-positive 8.1.6 cells (37, 38). Transfection of HLA-DMB into 9.5.3 cells restores the wild-type phenotype (36). Both 8.1.6 and 9.5.3 cells have been extensively characterized and are capable of presenting exogenously supplied peptides to specific T cells (39).

8.1.6 and 9.5.3 cells were electroporated with either DRA plus DRB1*0401 or DRA plus DRB1*0402 cDNAs on a pSVneo-plasmid containing the neomycin resistance gene (34, 40). Control 8.1.6 and 9.5.3 cells were electroporated with the DRA gene alone and will be referred to as DR4-null APC. Transfectants were selected by growth in 1 mg/ml G418. Single-cell clones were derived by limiting dilution.

Characterization of transfectants

Clones were characterized by flow cytometry using a panel of Abs including a DRB1*04-specific mAb, NFLD.D1 (41); a SE-specific mAb, NFLD.D2 (42); a DR dimer-specific mAb, L243 (43); a DRB1*04-specific mAb that recognizes an HLA-DM-dependent epitope NFLD.D11 (44); a DRB1*0401-specific mAb that recognizes an epitope on DM-null cells but not on DM-positive cells, NFLD.D13 (S. Drover, unpublished data); an irrelevant IgM Ab NS ‘M’ (TerraNova Biotechnology, Newfoundland, Canada); a CLIP-specific mAb, CerCLIP.1 (45); and a DRB1*0301-CLIP-specific mAb, 5-41 (E.D. Mellins, unpublished data). For FACS analysis, cells were incubated with primary Ab and washed twice with medium (RPMI 1640, 2 mM L-glutamine, 25 mM HEPES, 0.1% sodium azide, and 5% FCS, adjusted to pH 8). Bound Ab was detected using fluorescein-labeled goat anti-mouse IgG from Life Technologies or PE-labeled goat anti-Mouse IgM, µ-chain specific (Jackson ImmunoResearch, West Grove, PA). Cells were analyzed on a Becton Dickinson (Mountain View, CA) FACScan using CellQuest software. HLA-DM-positive and HLA-DM-null cells expressing comparable amounts of HLA-DR4 were selected on the basis of NFLD.D1 staining.

Surface peptide binding

Long chain biotinylated hemagglutinin peptide 307–319 (PKYVKQNTLKLAT) was obtained from Dr. Anand Gautam (M & E Biotech, Denmark) and was verified by mass spectrometry. Surface peptide binding was measured as described (46).

T hybridoma cells

Triple-transgenic mice, expressing HLA-DR4 (DRA *0101 and DRB1*0401 or DRB1*0402) and human CD4 on an I-A{beta}-/- background were generated as described (34). These mice were immunized with HCgp39 and T cell hybridomas were generated as described (34). Three immunodominant HCgp39 epitopes, which accounted for > 80% of the hybridomas generated, were identified from DR*0401-transgenic mice, and two distinct immunodominant epitopes accounting for 86% of the T cell hybridomas were identified from the DR*0402 mice (Ref. 34 ; see Table IGo). Peptides 22–37 and 298–313 were immunodominant in the context of DR*0402, but nonimmunogenic in DR*0401 mice, which were immunized with intact HCgp-39. Immunization of DR*0401 transgenic with these epitopes in free peptide form, resulted in the generation of T cell hybridomas that could respond to free peptide but not whole protein. Representative T hybridomas were selected from each category.


View this table:
[in this window]
[in a new window]
  		Table I. Immunodominant HCgp39 epitopes from HLA-DR4-transgenic mice

 
Ag presentation assays

The capacity of T cell hybridomas to respond to Ag was evaluated using either live, irradiated, or glutaraldehyde-fixed APCs. Live cells were irradiated (12,000 rad) with a cesium source. For fixed APC, cells were washed twice in Dulbecco’s PBS (DPBS) set at 106 cells/ml and fixed with 0.1% glutaraldehyde in DPBS for 15 s. The fixation process was stopped by adding an equal volume of 0.2 M L-lysine followed by two additional washes in DPBS. Adequate fixation was assessed by addition of 10 µl of 5 mg/ml MTT (Sigma, St. Louis, MO) to 100 µl of cells followed by incubation at 37°C for 4 h (47). Live cells convert the yellow tetrazolium salt into blue formazan crystals by the action of dehydrogenase enzymes while fixed cells do not. Irradiated and appropriately fixed cells were plated at 3–5 x 105 cells/well, preincubated for 30–60 min, with either HCgp39 protein or specific synthetic peptide (Research Genetics, Huntsville, AL) over a dose range of 0.1–5 µM. HCgp39 protein was purified from Chinese hamster ovary cells expressing HCgp39 cDNA from human articular chondrocytes (Organon, Oss, The Netherlands). B-LCL cells were cocultured with T hybridomas in the presence of Ag for 36 h at 37°C. T cell stimulation was measured using an IL-2 immunoassay (48). Briefly, IL-2 from the supernatant was captured with anti-IL-2 Ab (PharMingen, San Diego, CA), washed, and incubated with a biotin-conjugated anti-IL-2 Ab (PharMingen) in a sandwich immunoassay. Biotinylated IL-2 Ab was detected using a streptavidin europium read-out. The Ab was quantitated against a standard curve of recombinant IL-2 and europium fluorescence was measured on an LKB Wallac (Gaithersburg, MD) fluorometric plate reader. Results are expressed as the mean IL-2 amount of duplicate samples. Duplicates were generally within 1–5% of each other.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Generation and surface characterization of DRB1*0401- and DRB1*0402-transfected cells

To obtain cells that express HLA-DR4 alleles in the presence or absence of intracellular DM, we transfected HLA-DR4 cDNAs into B-LCL 8.1.6 (DR3, DQ2, DP4) and its HLA-DM-null derivative, 9.5.3. This approach ensured that, with the exception of HLA-DM, the cellular components of the Ag presentation machinery were the same in all the transfectants.

Bulk transfectant lines were generated by electroporation with plasmids encoding either DRA plus DRB*0401 or DRA plus DRB*0402, and single-cell clones were isolated by limiting dilution. The identities of the HLA-DR4-transfected cells were confirmed using Ab NFLD.D2, which is specific for the SE and recognizes DR*0401, but not DR*0402. NFLD.D2 recognizes an epitope that is poorly expressed in DM-null cells (42). Thus, 8.1.6 DR*0401 cells bound greater amounts of NFLD.D2 than 9.5.3 DR*0401 cells (Fig. 1Go). Levels of surface HLA-DR4 expression were determined by flow cytometry using the anti-DR4 Ab NFLD.D1 (Fig. 1Go). This Ab recognizes HLA-DR4 alleles in an HLA-DM-independent manner (41). We selected HLA-DM-positive (8.1.6) and HLA-DM-null (9.5.3) clonal transfectants with closely matched levels of DR*0401 (or DR*0402) surface expression to ensure that differences in MHC density would not contribute to differences in Ag presentation between these cells.



View larger version (45K):
[in this window]
[in a new window]
  		FIGURE 1. Transfected cells express the appropriate HLA-DR4 alleles on their surface. The bold lines represent binding of NFLD.D1 (anti-DR4), NFLD.D2 (anti-DRB1*0401), and CerCLIP.1 (anti-CLIP) Abs to HLA-DR4 expressing 8.1.6 (DM+) and 9.5.3 (DM-) cells used in the T cell assays. The last two panels are control cells transfected with the DRA gene alone. The majority of the CLIP expression on 8.1.6 (DM+) DRA cells represents DQ2/CLIP complexes (E. D. Mellins, unpublished data). Binding of secondary Ab alone is shown by the thin line.

 
In the absence of HLA-DM, CLIP peptide release from class II molecules is based on the intrinsic dissociation rate of CLIP/MHC class II complexes (27). We were interested in assessing the level of DR4/CLIP complexes on HLA-DM-null 9.5.3 cells expressing DR*0401 or DR*0402. HLA-DR4 expression on these cells was confirmed by binding of the NFLD.D1 Ab (Fig. 1Go). To detect DR-CLIP complexes, we used two DR-CLIP Abs, CerCLIP.1 and 5-41; CerCLIP.1 Ab binds to the N terminus of the CLIP fragment that extends beyond the peptide-binding groove (45). Thus CerCLIP.1 can detect both DR3-CLIP and DR4-CLIP complexes on the HLA-DM-null cells. However, the 5-41 Ab binds in an allele-specific manner and detects DR3-CLIP complexes but not DR4-CLIP complexes (E.D. Mellins, unpublished data). We observed equivalent or enhanced binding of CerCLIP.1 Ab to DR*04-transfected 9.5.3 cells as compared with untransfected 9.5.3 cells (Fig. 2GoA) indicating total numbers of DR-CLIP complexes on DR*04 cells were either equal to or greater than DR-CLIP complexes on untransfected cells. However, using the 5-41 Ab we detected a significant decrease in 5-41 binding to DR*04-transfected 9.5.3 cells over untransfected 9.5.3 cells (Fig. 2GoA) showing a reduction in DR3-CLIP complexes in the DR*04-transfected 9.5.3 cells. One likely explanation for this reduction is that the introduced {beta}-chains compete with DR3{beta}-chains for binding to DR{alpha}, which is hemizygous in these cells and may be limiting. Together, these data indicate that a significant proportion of the DR-CLIP complexes on the surface of DR*04-transfected 9.5.3 cells are DR4-CLIP complexes.



View larger version (35K):
[in this window]
[in a new window]
  		FIGURE 2. A, The presence of DR4/CLIP complexes on DM-null transfectants. A panel of Abs including CerCLIP.1 (anti-CLIP) and 5-41 (anti-DR3/CLIP) was used to characterize the HLA-DR4-transfected cells. The thin lines represent Ab binding to 9.5.3 cells transfected with DRA gene alone. The bold lines represent binding to DR*04-transfected 9.5.3 cells. B, Expression of DM-dependent and -independent epitopes on DRB1*0401-transfected cells. NFLD.D11 mAb recognizes an epitope on DRB1*0401 molecules on DM-positive cells, whereas NFLD.D13 recognizes an epitope on DRB1*0401 molecules on DM-null cells. The bold lines represent binding of the test Abs, and the thin lines represent binding of the nonspecific control Ab.

 
HLA-DM-null cells present previously characterized HLA-DM-independent epitopes

To verify that the HLA-DM-null DR*0401 cells were capable of presenting HLA-DM-independent epitopes, we examined these cells for the expression of HLA-DM-independent Ab epitopes and HLA-DM-inhibited Ab epitopes.

The HLA-DM-dependent Ab NFLD.D11 recognizes DR*0401-restricted epitopes in the presence of HLA-DM but not in its absence. We observed strong binding of NFLD.D11 to 8.1.6 DR*0401 cells and no recognition of 9.5.3 DR*0401 cells (Fig. 2GoB). Conversely, HLA-DM-independent Ab NFLD.D13, preferentially recognizes epitopes in the absence of HLA-DM but not in its presence. For NFLD.D13, we observed positive staining of 9.5.3 DR*0401 cells and no staining of 8.1.6 DR*0401 cells (Fig. 2GoB). Thus, the DM-null cells express epitopes that are suppressed in the presence of HLA-DM, and HLA-DM-positive cells express DM-dependent epitopes that the DM-null cells do not.

Peptide presentation of DR*0401 HCgp39 epitopes

To demonstrate that both the HLA-DM-positive and the HLA-DM-null DR*0401 APC were capable of stimulating the DR*0401-restricted T hybridomas, the APCs were incubated with synthetic peptides corresponding to the immunodominant epitopes, HCgp39 100–115, 262–277, and 322–337 (Fig. 3GoA). Peptides bind DR molecules predominantly at the cell surface (49), independent of intracellular HLA-DM. Both the HLA-DM-positive and the HLA-DM-null APC stimulated the T cells when pulsed with the appropriate peptides (Fig. 3GoA). No stimulation was observed in the absence of Ag or by DR4-null cells with Ag.



View larger version (37K):
[in this window]
[in a new window]
  		FIGURE 3. DM-null DR*0401 APC fail to present HCgp39 protein. DR*0401 APCs were incubated with either peptide Ag (A) or intact HCgp39 (B) at the concentrations shown and cocultured with DR*0401-restricted T hybridoma cells specific for HCgp39 epitopes 100–115, 262–277, and 313–322. T cell stimulation was assessed by an IL-2 immunoassay. The circles represent T cell stimulation by DM-positive DR*0401 APC; triangles represent DM-null DR4*0401 APC; stars represent DR4-null APC. T cell stimulatory activity is the mean of duplicate samples. Each experiment was performed three times with similar results. The inset shows response of the 100–115 T hybridoma at lower peptide doses. C, DM-null DR*0401 cells show greater surface peptide binding/exchange than DM-positive DR*0401 cells. Cells were incubated with a biotinylated HLA-DR4 binding, hemagglutinin peptide 307–319, and peptide binding was assessed using FITC-avidin. The bold lines represent binding to DR*0401 cells. The thin lines represent binding to untransfected cells. The dotted lines represent background binding of FITC-avidin to the DR*0401 and to untransfected cells in absence of peptide.

 
The HLA-DM-null DR*0401 cells were 6- to 8-fold more effective at peptide presentation than the HLA-DM-positive cells for the 262–277 and 322–337 epitopes, despite both cells having similar surface HLA-DR4 levels (Fig. 3GoA). We hypothesized that greater peptide presentation reflected greater surface peptide exchange on the DM-null DR*0401 cells. To test this hypothesis, we assessed the surface binding of a DR4-restricted peptide to DM-positive DR*0401 8.1.6 cells, DM-null DR*0401 9.5.3 cells, and to untransfected 8.1.6 and 9.5.3 cells. We observed over 10-fold higher binding of a stable DR*0401 binding peptide (hemagglutinin peptide 307–319) to DM-null DR*0401 cells as compared with DM-positive DR*0401 cells and little binding to untransfected cells (Fig. 3GoC).

For the 100–115 epitope, T cell stimulation was the about the same for both DM-null and DM-positive cells. It is likely that the 100–115 peptide binds better on DM-null cells than DM-positive cells, akin to other DR*0401 binding peptides. However, the 100–115-specific T hybridoma may require fewer complexes for maximal activation because it responds strongly at low peptide doses (Fig. 3GoB, inset).

Presentation of DR*0401 HCgp39 epitopes is HLA-DM dependent

To test whether efficient generation of the HCgp39 epitopes requires HLA-DM, we conducted Ag presentation assays using intact HCgp39 protein as the Ag. As shown in Fig. 3GoB, presentation of immunodominant epitopes of HCgp39 (100–115, 262–277, and 322–337) was significantly enhanced by intracellular HLA-DM. Under the conditions used, HLA-DM-null APC presented the DR*0401 epitope, 100–115, at much lower levels than DM-positive APC and failed to present epitopes 262–277 and 322–337 altogether. These findings do not reflect the unique properties of the particular APC clones used in these assays, because we obtained similar results using bulk DR*0401-transfected APC with and without intracellular HLA-DM (data not shown).

To examine whether cellular processing is required for presentation of the whole protein by the HLA-DM-positive APCs, we fixed the APC before the presentation assay. Fixation abolished protein presentation but not peptide presentation (Fig. 4Go) arguing that intracellular processing is required.



View larger version (31K):
[in this window]
[in a new window]
  		FIGURE 4. Glutaraldehyde-fixed APCs do not present HCgp39 protein but present specific peptides. DM-positive and DM-null DR*0401 and DR*0402 APCs, either live or fixed as indicated, were incubated with 5 µM HCgp39 intact protein or 5 µM specific peptide Ag and then cocultured with the indicated T cells. T cell stimulation was assayed by an IL-2 immunoassay. {blacksquare}, T cell stimulation by live irradiated cells; , fixed cells.

 
We observed that fixed cells presented peptides more efficiently than live DR*0401 cells (Fig. 4Go). Peptide loading occurs mainly on surface class II molecules in live 8.1.6 cells and though some peptide is endocytosed, it is rapidly degraded (49). Fixing the cells probably obliterates this phenomenon, hence equimolar amounts of peptide may be better presented by fixed cells.

Taken together, the data from the DR*0401-restricted T hybridomas indicated that the presentation of all three immunodominant HCgp39 epitopes was dependent or greatly augmented by expression of HLA-DM by the APC.

Presentation of HCgp39 epitopes restricted by DR*0402 requires HLA-DM

To assess whether HLA-DM dependence of the immunodominant epitopes was unique to the RA-associated DR*0401 allele, we tested the closely related HLA-DR4 allele, DRB1*0402, (not associated with RA) in a similar experiment using HCgp39-specific T cell hybridomas from DR*0402-transgenic mice. Both the HLA-DM-positive and HLA-DM-null DR*0402-expressing APC stimulated the T hybridomas when pulsed with the relevant synthetic peptides (Fig. 5GoA). No T cell response was observed with the DR*0402 APC in absence of Ag or with the control DR4-null cells with Ag (Fig. 5GoA). Unlike the results observed with DR*0401 APC, peptide presentation by HLA-DM-positive DR*0402-expressing cells was comparable to HLA-DM-null DR*0402-expressing cells. The lack of enhanced peptide presentation by live DM-null DR*0402 cells may reflect reduced surface peptide exchange at the surface of these cells as a result of the significantly higher affinity of DR*0402 for the CLIP peptide5.



View larger version (25K):
[in this window]
[in a new window]
  		FIGURE 5. DM-null DR*0402 APC do not present HCgp39 protein. DR*0402 APCs were incubated with either peptide Ag (A) or protein Ag (B) and cocultured with DRB1*0402-restricted T hybridoma cells specific for the HCgp39 22–37 and 298–313 epitopes. T cell stimulation was assessed by an IL-2 immunoassay. The circles represent T cell stimulation by DM-positive DR*0402 APC; triangles represent DM-null DR*0402 APC; stars represent DR4-null APC. T cell stimulatory activity is expressed as the mean of duplicate samples. Each experiment was performed at least twice.

 
In assays using intact HCgp39 protein as Ag, we observed efficient presentation of HCgp39 DR*0402 immunodominant epitopes (22–37 and 298–313) by the HLA-DM-positive APC (Fig. 5GoB). The HLA-DM-null APC presented the 298–313 epitope at much lower efficiency than the HLA-DM-positive cells and presented 22–37 very poorly, if at all. Fixation of the APCs abolished protein presentation but not peptide presentation as expected (Fig. 4Go). These results were reproduced with bulk DR*0402-transfected APC with and without intracellular HLA-DM (data not shown). Thus, similar to DR*0401 cells, HLA-DM-null DR*0402 APC were defective in presentation of intact protein.

HLA-DM-null cells do not present protein to "peptide-only" T cell hybridomas

Protein immunization of DR*0401 mice failed to produce any T cell hybridomas specific for HCgp39 epitope 22–37, which is an immunodominant epitope in DR*0402 mice. However, immunization of DR*0401 mice with synthetic peptides with amino acid sequences corresponding to HCgp39 22–37 produced T cell hybridomas (45G9 and 44E10) that recognized the peptide epitope but not whole protein. These hybridomas responded to DM-expressing APC incubated with peptide but not to cells incubated with intact HCgp39 protein as the Ag source. We hypothesized that complexes of these epitopes with DR*0401 may be susceptible to editing by HLA-DM. If so, then HLA-DM-null cells might express these epitopes after incubation with intact HCgp39 protein.

To test whether DM-null cells could present intact protein to peptide-only hybridomas, we incubated DM-null and DM-positive APC with protein and assayed stimulation of T hybridomas 45G9 and 44E10 (Fig. 6Go). No response to intact protein Ag was observed from either DM-positive or DM-null DR*0401 cells. However, these hybridomas did respond to specific peptide Ag incubated with either DM-positive or DM-null DR*0401 cells (Fig. 6Go), suggesting that these DR-peptide complexes are not generated from intact protein in DR*0401 cells.



View larger version (23K):
[in this window]
[in a new window]
  		FIGURE 6. DM-null APC do not present protein to peptide-only T hybridomas. APCs were incubated with either peptide or protein Ag and cocultured with DR*0401-restricted T hybridoma cells specific for HCgp39 22–37. The circles represent T cell stimulation with protein by DM-positive DR*0401 APC; triangles represent protein with DM-null DR*0401APC; hatched squares represent peptide with DM-positive DR*0401 APC; diamonds represent peptide with DM-null DR*0401 APC. T cell stimulatory activity is expressed as the mean of duplicate samples. Each experiment was performed at least twice.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
Autoimmunity may be associated with the presentation of previously "cryptic epitopes" of self-proteins to CD4+ T cells (50). We hypothesized that presentation of self-Ags by cells lacking functional HLA-DM might provide a mechanism for revealing new T cell epitopes to the immune system. This hypothesis is based on the observations that HLA-DM edits the repertoire of peptides displayed at the cell surface in favor of stable MHC/peptide complexes (9, 10, 51, 52). To test this hypothesis, we examined the role of DM in presentation to a panel of T cell hybridomas that recognize epitopes from a human cartilage autoantigen, HCgp39. These hybridomas were generated from transgenic mice, but are specific for determinants recognized by human T cells from DR4+ individuals. The epitopes recognized by the hybridomas were presented by HLA-DM-expressing APC and poorly, if at all by HLA-DM-null cells, after incubation with intact HCgp39. The requirement for HLA-DM expression is similar to that observed for presentation of various foreign Ags, such as tetanus toxoid (39). Thus, the lack of T cell tolerance to this autoantigen does not appear to be the consequence of its presentation by alternative pathways that generate previously cryptic determinants.

However, one caveat to our conclusion is that while the B-LCLs used in this study demonstrate a requirement for DM, they may not be representative of available APCs in vivo. For instance, B cells expressing Ag-specific receptors have been shown to be able to overcome the requirement for DM (53). Therefore, it remains a possibility that these HCgp39 epitopes maybe generated by DM-independent pathways in vivo.

Lack of exogenous protein presentation to T cells by DM-null APC has been associated with inefficient removal of CLIP from the class II molecules (36). However, peptide elution from surface DR*0401 complexes expressed in DM-null T2 cells reveals other self-peptides in addition to CLIP, indicating that some spontaneous dissociation of CLIP from DR*0401 occurs (54). Thus, we were surprised by the lack of presentation of the HCgp39 epitopes by HLA-DM-null DRB1*0401 cells incubated with whole protein. These peptides are probably generated in the DM-null cells because they are presented by the parental HLA-DM-positive 8.1.6 cells. We believe the lack of presentation may reflect a requirement of DR*0401 molecules for chaperoning by DM. A high proportion of MHC class II molecules may be irreversibly inactivated after spontaneous CLIP release in the late endosomal compartments (55, 56, 57). It is also possible that the HCgp39 epitopes are generated at low levels and do not compete well for presentation in the absence of HLA-DM editing of low affinity ligands.

The HCgp39 100–115 epitope was presented from intact protein by the HLA-DM-null DR*0401 cells, albeit at lower levels than by DM-positive cells. Because this epitope has roughly the same affinity for DR*0401 as the other two epitopes tested, the differences may be due to the sensitivity of the 100–115-specific T hybridoma, which may be activated by fewer complexes on the cell surface. Alternatively, this epitope may be generated in higher abundance, allowing it to compete well for binding sites made available after CLIP release. Another possibility is that this epitope is generated in the early endosomal compartments where the half-life of empty DR*0401 molecules may be longer because the environment is less acidic.

Peptide presentation for two of three HCgp39 epitopes by DM-null, DR*0401 cells was significantly more effective than peptide presentation by DM-positive DR*0401 cells. Our direct peptide binding results showed enhanced surface peptide exchange on DM-null compared with DM-positive DR*0401 cells using a labeled DR4-binding peptide that forms a long-lived complex. We believe this enhanced peptide binding and presentation by DR*0401 is attributable to the instability of the DR*0401-CLIP complex that reaches the cell surface in the absence of HLA-DM, thus resulting in generation of more empty, peptide-receptive class II molecules on the cell surface5. These peptide binding data are consistent with the hypothesis that some autoantigenic RA epitopes may be presented as a result of extracellular proteolysis and surface loading of class II molecules in the acidic synovial joint environment. However, this pathway need not be invoked to explain the activation of HCgp39 T cells in RA patients.

In this study we also examined the presentation pathway used by epitopes recognized by peptide-only HCgp39 T hybridomas. These hybridomas are similar to type-B T cells defined by Viner et al. (58) using the hen egg lysozyme Ag. The type-B T cells respond to APC incubated with synthetic peptide or even peptide eluted from MHC-peptide complexes generated by intracellular processing of intact HEL protein but not to APC incubated with intact protein (58). It is possible that these T cells recognize a specific peptide-MHC conformation generated by surface binding of peptide and this conformation is different from that generated by intracellular processing (58, 59). Intracellular processing in late endosomal compartments may be influenced by several factors including lower pH and presence of accessory molecule HLA-DM. Using peptide-only HCgp39-specific T hybridomas, we tested whether the lack of presentation of these specific epitopes from intact protein was a result of these complexes being edited out by HLA-DM. Our results show that absence of intracellular HLA-DM did not restore presentation of these epitopes from HCgp39 protein.

The HCgp39 epitopes were originally generated and presented in DR*04-transgenic mice that are H-2 M positive. The requirement for intracellular HLA-DM in human B cells for presentation of these epitopes implies that both HLA-DM and H-2 M interact with the HLA-DR4 molecules and favor the same MHC-peptide complexes for surface presentation. H-2 M and HLA-DM molecules have been recently crystallized (60, 61). The crystal structures indicate that though overall structures are conserved between the two molecules, there are several regions that are considerably different between H-2 M and HLA-DM (61). Our results suggest that despite these differences, HLA-DM and H-2 M may be functionally very similar.

Our data suggest that the traditional HLA-DM-dependent presentation pathway is involved in the presentation of autoantigenic HCgp39 epitopes. HCgp39 is a secreted protein and may be endocytosed for presentation by professional APCs present in the joint. However, in some autoimmune diseases nonprofessional APC have been postulated to be involved such as the cytokine-activated thyrocytes in thyroid disease (62). Recent work has shown that IFN-{gamma}-treated thyrocytes express HLA-DM{beta}, class II molecules, Ii and CIITA (62). Thus in some circumstances, the requirement for HLA-DM may be fulfilled by nonprofessional APCs that have been activated to express the machinery of the traditional Ag presentation pathway.


   Acknowledgments
 
We thank Dr. Robert Busch for helpful discussions and critical reading of the manuscript. We also thank Kevin Visconti for technical assistance in growing the T cell hybridomas.


   Footnotes
 
1 This work was supported by grants from the National Institute of Health, the Arthritis National Research Foundation, the Arthritis Foundation, and the Arthritis Research Campaign (U.K.). Back

2 Address correspondence and reprint requests to Dr. Namrata S. Patil, Department of Pediatric Immunology, Center for Clinical Sciences Research Building, Room 2120, 269 Campus Drive, Stanford, CA 94305. Back

3 E.D.M. and G.S. contributed equally to this work. Back

4 Abbreviations used in this paper: Ii, invariant chain; CLIP, class II-associated Ii peptide; SE, shared epitope; HCgp39, human cartilage glycoprotein 39; B-LCL, B lymphoblastoid cell line; RA, rheumatoid arthritis; DPBS, Dulbecco’s PBS. Back

5 N. S. Patil, W. Liu, M. Belmares, B. Kaneshiro, J. Rabinowitz, H. McConnell, and E. Mellins. Rheumatoid arthritis-associated HLA-DR alleles form less stable complexes with CLIP than a non-RA-associated HLA-DR allele. Submitted for publication. Back

Received for publication February 7, 2000. Accepted for publication September 27, 2000.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Ring, G. H., F. G. Lakkis. 1999. Breakdown of self-tolerance and the pathogenesis of autoimmunity. Semin. Nephrol. 19:25.[Medline]
  2. Ridgway, W. M., M. Fasso, C. G. Fathman. 1999. A new look at MHC and autoimmune disease. Science 284:749.[Free Full Text]
  3. Warnock, M. G., J. A. Goodacre. 1997. Cryptic T-cell epitopes and their role in the pathogenesis of autoimmune diseases. Br. J. Rheumatol. 36:1144.[Abstract/Free Full Text]
  4. Todd, J. A., H. Acha-Orbea, J. I. Bell, N. Chao, Z. Fronek, C. O. Jacob, M. McDermott, A. A. Sinha, L. Timmerman, L. Steinman, H. O. McDevitt. 1988. A molecular basis for MHC class II-associated autoimmunity: [Published erratum appears in 1988 Science 241:888.]. Science. 240:1003.[Abstract/Free Full Text]
  5. Wucherpfennig, K. W., B. Yu, K. Bhol, D. S. Monos, E. Argyris, R. W. Karr, A. R. Ahmed, J. L. Strominger. 1995. Structural basis for major histocompatibility complex (MHC)-linked susceptibility to autoimmunity: charged residues of a single MHC binding pocket confer selective presentation of self-peptides in pemphigus vulgaris. Proc. Natl. Acad. Sci. USA 92:11935.[Abstract/Free Full Text]
  6. Svejgaard, A., P. Platz, L. P. Ryder. 1983. HLA and disease 1982-a survey. Immunol. Rev. 70:193.[Medline]
  7. Busch, R., E. D. Mellins. 1996. Developing and shedding inhibitions: how MHC class II molecules reach maturity. Curr. Opin. Immunol. 8:51.[Medline]
  8. Busch, R., R. C. Doebele, N. S. Patil, A. P. Pashine, and E. D. Mellins. 2000. Accessory molecules of MHC class II peptide loading. Curr. Opin. Immunol.
  9. Katz, J. F., C. Stebbins, E. Appella, A. J. Sant. 1996. Invariant chain and DM edit self-peptide presentation by major histocompatibility complex (MHC) class II molecules. J. Exp. Med. 184:1747.[Abstract/Free Full Text]
  10. Sloan, V. S., P. Cameron, G. Porter, M. Gammon, M. Amaya, E. Mellins, D. M. Zaller. 1995. Mediation by HLA-DM of dissociation of peptides from HLA-DR. Nature 375:802.[Medline]
  11. Weber, D. A., B. D. Evavold, P. E. Jensen. 1996. Enhanced dissociation of HLA-DR-bound peptides in the presence of HLA-DM. Science 274:618.[Abstract/Free Full Text]
  12. Joosten, I., M. H. Wauben, M. C. Holewijn, K. Reske, L. O. Pedersen, C. F. Roosenboom, E. J. Hensen, W. van Eden, S. Buus. 1994. Direct binding of autoimmune disease related T cell epitopes to purified Lewis rat MHC class II molecules. Int. Immunol. 6:751.[Abstract/Free Full Text]
  13. Fairchild, P. J., R. Wildgoose, E. Atherton, S. Webb, D. C. Wraith. 1993. An autoantigenic T cell epitope forms unstable complexes with class II MHC: a novel route for escape from tolerance induction. Int. Immunol. 5:1151.[Abstract/Free Full Text]
  14. Mason, K., Jr D. W. Denney, H. M. McConnell. 1995. Myelin basic protein peptide complexes with the class II MHC molecules I-Au and I-Ak form and dissociate rapidly at neutral pH. J. Immunol. 154:5216.[Abstract]
  15. de Graaf, K. L., R. Weissert, P. Kjellen, R. Holmdahl, T. Olsson. 1999. Allelic variations in rat MHC class II binding of myelin basic protein peptides correlate with encephalitogenicity. Int. Immunol. 11:1981.[Abstract/Free Full Text]
  16. Wall, M., S. Southwood, J. Sidney, C. Oseroff, M. F. del Guericio, A. G. Lamont, S. M. Colon, T. Arrhenius, F. C. Gaeta, A. Sette. 1992. High affinity for class II molecules as a necessary but not sufficient characteristic of encephalitogenic determinants. Int. Immunol. 4:773.[Abstract/Free Full Text]
  17. Congia, M., S. Patel, A. P. Cope, S. De Virgiliis, G. Sonderstrup. 1998. T cell epitopes of insulin defined in HLA-DR4-transgenic mice are derived from preproinsulin and proinsulin. Proc. Natl. Acad. Sci. USA 95:3833.[Abstract/Free Full Text]
  18. Chao, C. C., H. K. Sytwu, E. L. Chen, J. Toma, H. O. McDevitt. 1999. The role of MHC class II molecules in susceptibility to type I diabetes: identification of peptide epitopes and characterization of the T cell repertoire. Proc. Natl. Acad. Sci. USA 96:9299.[Abstract/Free Full Text]
  19. Harfouch-Hammoud, E., T. Walk, H. Otto, G. Jung, J. F. Bach, P. M. van Endert, S. Caillat-Zucman. 1999. Identification of peptides from autoantigens GAD65 and IA-2 that bind to HLA class II molecules predisposing to or protecting from type 1 diabetes. Diabetes 48:1937.[Abstract]
  20. Matsuo, H., A. P. Batocchi, S. Hawke, M. Nicolle, L. Jacobson, A. Vincent, J. Newsom-Davis, N. Willcox. 1995. Peptide-selected T cell lines from myasthenia gravis patients and controls recognize epitopes that are not processed from whole acetylcholine receptor. J. Immunol. 155:3683.[Abstract]
  21. Nepom, G. T., B. S. Nepom. 1992. Prediction of susceptibility to rheumatoid arthritis by human leukocyte antigen genotyping. Rheum. Dis. Clin. N. Am. 18:785.[Medline]
  22. Weyand, C. M., K. C. Hicok, D. L. Conn, J. J. Goronzy. 1992. The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis. Ann. Intern. Med. 117:801.
  23. Thomson, W., B. Harrison, B. Ollier, N. Wiles, T. Payton, J. Barrett, D. Symmons, A. Silman. 1999. Quantifying the exact role of HLA-DRB1 alleles in susceptibility to inflammatory polyarthritis: results from a large, population-based study. Arthritis Rheum. 42:757.[Medline]
  24. Gregersen, P. K., J. Silver, R. J. Winchester. 1987. The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 30:1205.[Medline]
  25. Winchester, R.. 1994. The molecular basis of susceptibility to rheumatoid arthritis. Adv. Immunol. 56:389.[Medline]
  26. Dessen, A., C. M. Lawrence, S. Cupo, D. M. Zaller, D. C. Wiley. 1997. X-ray crystal structure of HLA-DR4 (DRA*0101, DRB1*0401) complexed with a peptide from human collagen II. Immunity 7:473.[Medline]
  27. Sette, A., S. Southwood, J. Miller, E. Appella. 1995. Binding of major histocompatibility complex class II to the invariant chain-derived peptide, CLIP, is regulated by allelic polymorphism in class II. J. Exp. Med. 181:677.[Abstract/Free Full Text]
  28. Bikoff, E. K., R. N. Germain, E. J. Robertson. 1995. Allelic differences affecting invariant chain dependency of MHC class II subunit assembly. Immunity. 2:301.[Medline]
  29. Hakala, B. E., C. White, A. D. Recklies. 1993. Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J. Biol. Chem. 268:25803.[Abstract/Free Full Text]
  30. Hu, B., K. Trinh, W. F. Figueira, P. A. Price. 1996. Isolation and sequence of a novel human chondrocyte protein related to mammalian members of the chitinase protein family. J. Biol. Chem. 271:19415.[Abstract/Free Full Text]
  31. Johansen, J. S., H. S. Jensen, P. A. Price. 1993. A new biochemical marker for joint injury: analysis of YKL-40 in serum and synovial fluid. Br. J. Rheumatol. 32:949.[Abstract/Free Full Text]
  32. Johansen, J. S., M. Stoltenberg, M. Hansen, A. Florescu, K. Horslev-Petersen, I. Lorenzen, P. A. Price. 1999. Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity. Rheumatology 38:618.[Abstract/Free Full Text]
  33. Verheijden, G. F., A. W. Rijnders, E. Bos, C. J. Coenen-de Roo, C. J. van Stoveren, A. M. Miltenburg, J. H. Meijerink, D. Elewaut, F. de Keyser, E. Veys, A. M. Boots. 1997. Human cartilage glycoprotein-39 as a candidate autoantigen in rheumatoid arthritis. Arthritis Rheum. 40:1115.[Medline]
  34. Cope, A. P., S. D. Patel, F. Hall, M. Congia, H. A. Hubers, G. F. Verheijden, A. M. Boots, R. Menon, M. Trucco, A. W. Rijnders, G. Sonderstrup. 1999. T cell responses to a human cartilage autoantigen in the context of rheumatoid arthritis-associated and nonassociated HLA-DR4 alleles. Arthritis Rheum. 42:1497.[Medline]
  35. Mellins, E., M. Woelfel, D. Pious. 1987. Importance of HLA-DQ and -DP restriction elements in T-cell responses to soluble antigens: mutational analysis. Hum. Immunol. 18:211.[Medline]
  36. Morris, P., J. Shaman, M. Attaya, M. Amaya, S. Goodman, C. Bergman, J. J. Monaco, E. Mellins. 1994. An essential role for HLA-DM in antigen presentation by class II major histocompatibility molecules. Nature 368:551.[Medline]
  37. Mellins, E., P. Cameron, M. Amaya, S. Goodman, D. Pious, L. Smith, B. Arp. 1994. A mutant human histocompatibility leukocyte antigen DR molecule associated with invariant chain peptides. J. Exp. Med. 179:541.[Abstract/Free Full Text]
  38. Guerra, C. B., R. Busch, R. C. Doebele, W. Liu, T. Sawada, W. W. Kwok, M. D. Chang, E. D. Mellins. 1998. Novel glycosylation of HLA-DR{alpha} disrupts antigen presentation without altering endosomal localization. J. Immunol. 160:4289.[Abstract/Free Full Text]
  39. Mellins, E., L. Smith, B. Arp, T. Cotner, E. Celis, D. Pious. 1990. Defective processing and presentation of exogenous antigens in mutants with normal HLA class II genes. Nature 343:71.[Medline]
  40. Fugger, L., S. A. Michie, I. Rulifson, C. B. Lock, G. S. McDevitt. 1994. Expression of HLA-DR4 and human CD4 transgenes in mice determines the variable region {beta}-chain T-cell repertoire and mediates an HLA-DR-restricted immune response. Proc. Natl. Acad. Sci. USA 91:6151.[Abstract/Free Full Text]
  41. Kovats, S., S. Drover, W. H. Marshall, D. Freed, P. E. Whiteley, G. T. Nepom, J. S. Blum. 1994. Coordinate defects in human histocompatibility leukocyte antigen class II expression and antigen presentation in bare lymphocyte syndrome. J. Exp. Med. 179:2017.[Abstract/Free Full Text]
  42. Drover, S., R. W. Karr, X. T. Fu, W. H. Marshall. 1994. Analysis of monoclonal antibodies specific for unique and shared determinants on HLA-DR4 molecules. Hum. Immunol. 40:51.[Medline]
  43. Lampson, L. A., R. Levy. 1980. Two populations of Ia-like molecules on a human B cell line. J. Immunol. 125:293.[Abstract]
  44. Drover, S., S. Kovats, S. Masewicz, J. S. Blum, G. T. Nepom. 1998. Modulation of peptide-dependent allospecific epitopes on HLA-DR4 molecules by HLA-DM. Hum. Immunol. 59:77.[Medline]
  45. Denzin, L. K., N. F. Robbins, C. Carboy-Newcomb, P. Cresswell. 1994. Assembly and intracellular transport of HLA-DM and correction of the class II antigen-processing defect in T2 cells. Immunity. 1:595.[Medline]
  46. Busch, R., J. B. Rothbard. 1990. Detection of peptide-MHC class II complexes on the surface of intact cells. J. Immunol. Methods 134:1.[Medline]
  47. Mosmann, T.. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65:55.[Medline]
  48. Patel, S. D., A. P. Cope, M. Congia, T. T. Chen, E. Kim, L. Fugger, D. Wherrett, G. Sonderstrup-McDevitt. 1997. Identification of immunodominant T cell epitopes of human glutamic acid decarboxylase 65 by using HLA-DR ({alpha}1*0101,{beta}1*0401)-transgenic mice. Proc. Natl. Acad. Sci. USA 94:8082.[Abstract/Free Full Text]
  49. Monji, T., D. Pious. 1997. Exogenously provided peptides fail to complex with intracellular class II molecules for presentation by antigen-presenting cells. J. Immunol. 158:3155.[Abstract]
  50. Sercarz, E. E., P. V. Lehmann, A. Ametani, G. Benichou, A. Miller, K. Moudgil. 1993. Dominance and crypticity of T cell antigenic determinants. Annu. Rev. Immunol. 11:729.[Medline]
  51. van Ham, S. M., U. Gruneberg, G. Malcherek, I. Broker, A. Melms, J. Trowsdale. 1996. Human histocompatibility leukocyte antigen (HLA)-DM edits peptides presented by HLA-DR according to their ligand binding motifs. J. Exp. Med. 184:2019.[Abstract/Free Full Text]
  52. Kropshofer, H., A. B. Vogt, G. Moldenhauer, J. Hammer, J. S. Blum, G. J. Hammerling. 1996. Editing of the HLA-DR-peptide repertoire by HLA-DM. EMBO J. 15:6144.[Medline]
  53. Ma, C., J. S. Blum. 1997. Receptor-mediated endocytosis of antigens overcomes the requirement for HLA-DM in class II-restricted antigen presentation. J. Immunol. 158:1.[Abstract]
  54. Avva, R. R., P. Cresswell. 1994. In vivo and in vitro formation and dissociation of HLA-DR complexes with invariant chain-derived peptides. Immunity 1:763.[Medline]
  55. Germain, R. N., Jr A. G. Rinker. 1993. Peptide binding inhibits protein aggregation of invariant-chain free class II dimers and promotes surface expression of occupied molecules. Nature 363:725.[Medline]
  56. Kropshofer, H., S. O. Arndt, G. Moldenhauer, G. J. Hammerling, A. B. Vogt. 1997. HLA-DM acts as a molecular chaperone and rescues empty HLA-DR molecules at lysosomal pH. Immunity 6:293.[Medline]
  57. Vogt, A. B., G. Moldenhauer, G. J. Hammerling, H. Kropshofer. 1997. HLA-DM stabilizes empty HLA-DR molecules in a chaperone-like fashion. Immunol. Lett. 57:209.[Medline]
  58. Viner, N. J., C. A. Nelson, B. Deck, E. R. Unanue. 1996. Complexes generated by the binding of free peptides to class II MHC molecules are antigenically diverse compared with those generated by intracellular processing. J. Immunol. 156:2365.[Abstract]
  59. Rabinowitz, J. D., K. Tate, C. Lee, C. Beeson, H. M. McConnell. 1997. Specific T cell recognition of kinetic isomers in the binding of peptide to class II major histocompatibility complex. Proc. Natl. Acad. Sci. USA 94:8702.[Abstract/Free Full Text]
  60. Mosyak, L., D. M. Zaller, D. C. Wiley. 1998. The structure of HLA-DM, the peptide exchange catalyst that loads antigen onto class II MHC molecules during antigen presentation. Immunity 9:377.[Medline]
  61. Fremont, D. H., F. Crawford, P. Marrack, W. A. Hendrickson, J. Kappler. 1998. Crystal structure of mouse H2-M. Immunity 9:385.[Medline]
  62. Wu, Z., P. A. Biro, R. Mirakian, L. Hammond, F. Curcio, F. S. Ambesi-Impiombato, G. F. Bottazzo. 1999. HLA-DMB expression by thyrocytes: indication of the antigen-processing and possible presenting capability of thyroid cells. Clin. Exp. Immunol. 116:62.[Medline]



This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
A. P. Cope
Exploring the reciprocal relationship between immunity and inflammation in chronic inflammatory arthritis
Rheumatology, June 1, 2003; 42(6): 716 - 731.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. C. Tsark, W. Wang, Y.-C. Teng, D. Arkfeld, G. R. Dodge, and S. Kovats
Differential MHC Class II-Mediated Presentation of Rheumatoid Arthritis Autoantigens by Human Dendritic Cells and Macrophages
J. Immunol., December 1, 2002; 169(11): 6625 - 6633.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
N. S. Patil, A. Pashine, M. P. Belmares, W. Liu, B. Kaneshiro, J. Rabinowitz, H. McConnell, and E. D. Mellins
Rheumatoid Arthritis (RA)-Associated HLA-DR Alleles Form Less Stable Complexes with Class II-Associated Invariant Chain Peptide Than Non-RA-Associated HLA-DR Alleles
J. Immunol., December 15, 2001; 167(12): 7157 - 7168.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Patil, N. S.
Right arrow Articles by Mellins, E. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Patil, N. S.
Right arrow Articles by Mellins, E. D.
Right arrowPubmed/NCBI databases
*Substance via MeSH

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS